Nephrogenic diabetes insipidus (NDI) is usually caused by a lack of responsiveness of the collecting ducts to the arginine vasopressin (AVP). It is characterized by excessive urinary output caused by impaired urinary concentration ability. In severe cases, adult patients excrete more than 10 L per day, making them at constant risk for severe dehydration. Water homeostasis critically depends on replenishing water loss, and this compensatory fluid intake, combined with the continuous large diuresis, significantly impairs activities of daily living.[@bib1] No causal treatment for the disease exists, and current approaches for symptomatic treatment aim to ameliorate symptoms with adequate water supply, nonspecific pharmacological therapies and dietary restrictions, as reviewed elsewhere.[@bib2] The diagnosis of congenital NDI is often reached in infancy; clinical findings include polyuria, polydipsia, hypernatremia, plasma hyperosmolality, and hypoosmolar urine.[@bib3] In NDI, there is a normal increase in vasopressin/copeptin plasma concentrations during water deprivation but no sensitivity to exogenous or endogenous AVP.[@bib3] Nephrogenic diabetes insipidus results from impaired vasopressin receptor signaling at target cells or defect aquaporins, and may be acquired (secondary NDI) or congenital (primary NDI).[@bib4] Primary NDI can be caused by mutations in genes encoding aquaporin 2 (AQP2) (autosomal recessive/dominant, 10% of primary NDI cases) or the arginine vasopressin 2 (AVP-V2) receptor (X-linked, 90% of primary NDI cases).[@bib1] Activation of the AVP-V2 receptor promotes water reabsorption through increases in intracellular cyclic adenosine monophosphate (cAMP) level and protein kinase A activity ([Figure 1](#fig1){ref-type="fig"}a). No treatment has yet efficiently bypassed an inactive AVP-V2 receptor to raise cAMP in principal cells. *In vitro* studies found a cAMP-independent effect of nitric oxide, L-arginine, and atrial natriuretic peptide to increase the translocation of AQP2 from the cytoplasm to the apical membrane through an increase in cyclic guanosine monophosphate (cGMP).[@bib5] Similarly, in mouse cortical collecting duct cells, atrial natriuretic peptide, L-arginine, and 8-bromoguanosine 3\'5\' cGMP-induced translocation of AQP2.[@bib6] In accordance with these results, the phosphodiesterase type 5 (PDE5) inhibitor sildenafil, which inhibits cGMP degradation, increased the apical redistribution of AQP2 *in vitro* and *in vivo* in rats.[@bib7] In rats with lithium-induced acquired NDI, sildenafil reduced urinary output and increased the medullary expression of AQP2.[@bib8] To our knowledge, the only report of such an effect in humans is a case report with data from a 4.5-year-old boy with X-linked NDI. Administration of sildenafil for 10 days significantly reduced 24-hour urinary output, increased urinary osmolality, and normalized serum osmolality.[@bib9] Thus, it appears that the AVP-V2 receptor pathway can be circumvented through an alternative cGMP-mediated pathway. This may offer a potential treatment strategy in patients with NDI due to an AVP-V2 receptor mutation. We previously identified a new X-linked mutation in the AVP-V2 receptor in male dizygotic twins in our outpatient clinic and characterized their phenotype ([Figure 1](#fig1){ref-type="fig"}b).[S1](#appsec1){ref-type="sec"} Here, we present the results of a clinical trial testing the hypothesis that the PDE5-inhibitor sildenafil or the soluble guanylate cyclase (sGC) stimulator riociguat would reduce 24-hour diuresis and water intake and improve urinary concentration ability during water deprivation in 2 male subjects with severe congenital NDI due to a hemizygous mutation in exon 2 of AVPR2 gene: AVPR2:c.C840G;p.R137G ([Figure 1](#fig1){ref-type="fig"}a).[S1](#appsec1){ref-type="sec"}Figure 1(a) Schematic presentation of the arginine vasopressin (AVP)−mediated trafficking of aquaporin 2 (AQP2) in the principal cells of the collecting ducts and 2 potential treatment strategies for treating nephrogenic diabetes insipidus (NDI). Binding of the AVP to the G protein−coupled transmembrane vasopressin receptor (V2R) located in the basolateral membrane of the principal cell stimulates the release of Gsα, which in turn increases the conversion of adenosine monophosphate (AMP) to cyclic AMP (cAMP). Increased levels of cAMP activate protein kinase A (PKA), which subsequently phosphorylates several residues on the c-terminus of AQP2 and enables trafficking and insertion of AQP2 to the apical membrane as well as facilitates water diffusion along concentration gradients. Water exits the cell by AQP3 and AQP4 constitutively located in the basolateral membrane. Administration of a phosphodiesterase type 5 (PDE5) inhibitor sildenafil or a soluble guanylate cyclase stimulator, riociguat, increases cyclic guanosine monophosphate (cGMP), which potentially could activate PKA and allow trafficking of AQP2. We report the results of these 2 potential treatment strategies for treatment of NDI caused by mutation in the V2R. (b) Illustration of the transmembrane V2R. In the highlighted area, residue 137 is indicated. Mutation results in substitution of glycine for arginine and loss-of-function of the V2R and inappropriate response to AVP stimulation, which results in NDI.

Results {#sec1}
=======

Baseline characteristics are listed in [Table 1](#tbl1){ref-type="table"}. Both subjects were obese, with a body mass index of 43.4 and 42.7 kg/m^2^, respectively. Blood pressures were within normal range at 127/72 mm Hg and 131/65 mm Hg. Paraclinical values showed slight hypernatremia (146 mmol/l in both subjects), plasma osmolality in the high-normal range (300 mmol/kg), hypokalemia (3.2 and 3.4 mmol/l), and hypomagnesemia (0.62 and 0.66 mmol/l) ([Table 1](#tbl1){ref-type="table"}). Both subjects had excessive 24-hour urinary output (10,475 and 11,275 ml/d) with unmeasurable urine sodium concentration and a very low urinary osmolality (97 and 92 mosm/kg), and displayed hyperfiltration as judged by creatinine clearances above 150 ml/min ([Table 1](#tbl1){ref-type="table"}).Table 1Baseline characteristicsCharacteristicSubject 1Subject 2Reference valuesBodyweight (kg)144.6142.4Height (cm)182.5182.5Body mass index (kg/cm^2^)43.442,8SBP (mm Hg)127131DBP (mm Hg)7265Pulse (min^−1^)9590BloodHemoglobin (mmol/l)9.810.28.3--10.5Calcium ion (mmol/l)1.231.251.18--1.32Phosphate (mmol/l)0.910.910.71--1.53Magnesium (mmol/l)**0.620.66**0.71--0.94Sodium (mmol/l)**146146**137--145Potassium (mmol/l)**3.23.4**3.5--4.4Albumin (g/l)454636--50Creatinine (μmol/l)686360--105eGFR (ml/min)\>90\>90\>59Bicarbonate (mmol/l)2425.822--26Alanine transaminase (U/l)191610--70Glucose (mmol/l)7.15.62.5--11.0C-reactive protein (mg/l)8.93.9\<6Osmolality (mosm/kg)**300300**280--300UrineVolume (ml/d)**10,47511,275**Creatinine clearance (ml/min)**154155**70--150Protein (g/l)\<0.04\<0.04Sodium (mmol/l)**\<20\<20**Potassium (mmol/l)77Osmolality (mosm/kg)**9792**300--900

Effect of Sildenafil and Riociguat on Urinary and Plasma Parameters {#sec1.1}
-------------------------------------------------------------------

[Figure 2](#fig2){ref-type="fig"}a illustrates the study timeline. Sildenafil and riociguat treatment increased cGMP excretion in 24-hour urine samples during each treatment period compared to baseline samples ([Table 2](#tbl2){ref-type="table"}). Plasma cGMP increased but did not show a fold change similar to that in urine. Systolic blood pressure decreased in both subjects during treatment, whereas diastolic blood pressure remained stable ([Figure 2](#fig2){ref-type="fig"}b). Treatment with sildenafil did not affect urine output or urine osmolality in the first 4 days; in the last 2 days, 24-hour urinary output declined, but was still at 9 to 10 L/d ([Figure 2](#fig2){ref-type="fig"}c). In response to treatment with riociguat, urinary output declined during the first 2 days from very high values (15 L/d) and then increased again to levels above 10 L/d. For both subjects, these fluctuations in urinary output were not accompanied by marked changes in urine osmolality, which was 90 to 100 mosm/kg throughout both observation periods ([Fig. 2](#fig2){ref-type="fig"}c). For both subjects, plasma osmolality and plasma sodium concentrations were stable above normal reference range (approximately 300 mosm/kg and 145−150 mmol/l) during both intervention periods ([Figure 2](#fig2){ref-type="fig"}d). For both subjects, creatinine clearance declined to near-normal levels in response to sildenafil and in 1 of the subjects in response to riociguat. The other subject had no effect of riociguat on creatinine clearance ([Figure 2](#fig2){ref-type="fig"}e). Fractional excretion of K^+^ was 10% to 15% and fluctuated within this interval ([Figure 2](#fig2){ref-type="fig"}f). Fractional excretion of Na^+^ could not be calculated because of unmeasurable urinary Na^+^ concentrations.Figure 2(a) Illustration of the chronological timeline of the experiment. At baseline, the subjects collected 24-hour urinary samples, underwent blood sampling, and performed a water deprivation test. The first part of the study was performed with administration of sildenafil 50 mg 3 times a day for a total of 7 days. The experiment was initiated with hospitalization for 3 days and subsequent daily control in the outpatient clinic at the nephrology department. The last day of treatment, a water deprivation test was carried out. After a washout period, the second part of the experiment was conducted in a similar way, with administration of riociguat 1 mg × 3/d for 7 days. (b−f) Diagram illustrating the effects of treatment with sildenafil or riociguat compared to baseline samples on blood pressure, urinary output and osmolality, plasma sodium and osmolality, creatinine clearance and fractional excretion of potassium. Dia BP, diastolic blood pressure; sGC, soluble guanylate cyclase; Sys BP, systolic blood pressure.Table 2Cyclic guanosine monophosphate (cGMP) measurementscGMP measurementBasisSildenafilRiociguatSubject 1Subject 2Subject 1Subject 2Subject 1Subject 2Plasma cGMP (pmol/ml)7.675.516.5210.746.628.2924-h Urinary cGMP (nmol/d)964.75821.951179.171118.221741.711234.49Crude urine cGMP/crea (μmol/g)[a](#tbl2fna){ref-type="table-fn"}0.380.410.560.651.030.45[^2]

Effect of Sildenafil and Riociguat on Urinary Concentration Ability {#sec1.2}
-------------------------------------------------------------------

Water deprivation did not reduce urinary output, which was around 600 ml/h in both subjects ([Figure 3](#fig3){ref-type="fig"}a), with a corresponding weight loss of 2 to 4 kg during 4 hours of water deprivation ([Figure 3](#fig3){ref-type="fig"}a). After the intervention with sildenafil or riociguat, urinary output remained unaltered at values greater than 500 ml/h, as did body weight loss ([Figure 3](#fig3){ref-type="fig"}e and i). This was paralleled by a decrease in total body water as judged by bioimpedance ([Figure 3](#fig3){ref-type="fig"}b, f, and j). Plasma osmolality increased gradually throughout water deprivation at baseline and after both interventions to maximal levels of 315 mosm/kg; however, urinary osmolality increased only slightly during water deprivation, with no differences before and after the interventions and with maximal levels attained at 130 mosm/kg ([Figure 3](#fig3){ref-type="fig"}c, g, and k). Plasma sodium concentrations increased to peak levels of 154 mmol/l, with no difference between baseline and intervention ([Figure 3](#fig3){ref-type="fig"}d, h, and l). Plasma levels of AVP increased to levels around 7.8 pmol/l during water deprivation and were not affected by sildenafil or riociguat ([Figure 3](#fig3){ref-type="fig"}d, h, and l). Water deprivation tests in both experimental runs and in both probands were terminated after 3 to 4 hours because of plasma sodium levels reaching the predefined safety level of 150 mmol/l.Figure 3Diagram showing the effects of water deprivation test at baseline (a−d) and during treatment with sildenafil (e−h) and riociguat (i−l). During water deprivation, urinary volume was continuously high, which resulted in a significant weight loss. Plasma osmolality increased, whereas urinary osmolality was unchanged and low. Plasma arginine vasopressin (AVP) concentration increased in parallel to increased plasma sodium concentration. Despite treatment with sildenafil or riociguat, none of the subjects were able to concentrate their urine during water deprivation. Stop-criteria were attained after 3 to 4 hours, and water deprivation was abolished.

Side Effects of Sildenafil and Riociguat {#sec1.3}
----------------------------------------

The subjects experienced transient upper gastrointestinal symptoms, headaches, and flushing during treatment with sildenafil. Moreover, at the end of the treatment period with sildenafil, both subjects developed mild muscle pain, especially in the lower limbs. Riociguat was generally well accepted, although 1 subject again experienced dyspepsia.

Discussion {#sec2}
==========

The current study investigated the hypothesis that drugs stimulating the cGMP pathway would reduce 24-hour urinary output and improve urinary concentration ability during water deprivation in 2 subjects with congenital NDI due to mutation in the AVPR2 gene. The subjects displayed markedly increased urinary output at approximately 10 to 11 L/d at baseline with low urine osmolality, and although the PDE5-inhibitor sildenafil and the sGC-stimulator riociguat both increased urinary cGMP and lowered blood pressure and hyperfiltration, they had no consistent beneficial effect on urine concentration capacity or urine output, plasma osmolality, or sodium concentration in these subjects. Both treatment strategies were well tolerated without significant side effects.

Experimental data have demonstrated accumulation of AQP2 in the apical membrane of renal collecting ducts in rats with central DI treated with sildenafil, suggesting a vasopressin-independent AQP2 membrane insertion induced by cGMP-mediated signal pathway.[@bib7] However, in mice with knock-out of the AVP-V2 receptors, the only systemic therapy proved to lower diuresis and improve urine concentrating ability and AQP2 trafficking was a cAMP-dependent PGE~2~-EP4 receptor agonist[S2](#appsec1){ref-type="sec"}, a combination of fluvastatin and secretin,[S3](#appsec1){ref-type="sec"} or metformin.[S4](#appsec1){ref-type="sec"}^,^[S5](#appsec1){ref-type="sec"} A functional beneficial effect of sildenafil or other cGMP-dependent agonists measured as increased urine concentration ability has not been demonstrated in male mice with loss-of-function of AVPR2. Thus, although treatment with cGMP seems to be a promising approach to treat NDI patients based on experimental data, validation studies in patients with NDI are lacking because of the rarity of the disease. A study published during the present investigation tested AVP-independent urine concentrating capacity in healthy volunteers treated with sildenafil and showed no effect on urinary osmolality.[S6](#appsec1){ref-type="sec"} These results are in accordance with the present study, but are in contrast to a previous report of a 4.5-year-old boy with congenital NDI also caused by AVPR2 mutation. Here, sildenafil (2 mg/kg per day) reduced urinary output, increased urine osmolality, and normalized plasma sodium and plasma osmolality.[@bib9] These contrasting results could partly be explained by physiological or pharmacodynamic differences between children and adults. It has previously been noted that the effects of standard treatment in NDI may decrease during adolescence.[S7](#appsec1){ref-type="sec"} After termination of the present study, both patients were referred for urodynamic examinations, which revealed a residual volume of 120 to 160 ml after a voided volume of 570 ml and of 530 to 600 ml after a voided volume of 709 ml. It could be speculated that progressive tubulo-interstitial damage resulting from years of high tubular flow rates and high-volume voiding, could lead to less reversibility of polyuria in adults.

Another explanation could be the difference in dosages. In the current study, the sildenafil dosage was approximately 1 mg/kg per day (150 mg daily), whereas the pediatric patient received twice that dosage (2 mg/kg per day).[@bib9] A dosage of 1 mg/kg per day is within the high therapeutic range; in addition, because of side effects and a significant drop in systolic blood pressure, it would not have been feasible to increase dosages in the present study.

Although hydrochlorothiazide and a sodium-restricted diet might attenuate symptoms in NDI,[S8](#appsec1){ref-type="sec"} no causal treatment for the disease exists. Previously, a cross-over study was designed to investigate the effect of sildenafil 100 to 200 mg/d combined with calcitonin for 4 days in addition to standard therapy with hydrochlorothiazide/amiloride and indomethacin in 40 NDI patients 5 to 25 years of age. This study was terminated after completing 4 patients with no effect of sildenafil/calcitonin addition on 24-h urinary volumes compared with standard treatment (unpublished, [clinicaltrials.gov:](http://clinicaltrials.gov:){#interref0010} NCT00478335).

To our knowledge, this is the first study to test the effect of riociguat in the context of NDI. From the hypothesis, a better tolerance to water deprivation after treatment with sildenafil and riociguat was predicted; however, this was not observed. Hypernatremia led to termination of the water deprivation tests 1 hour earlier after treatment with sildenafil compared to baseline. In 1 of the subjects, this was partly due to higher start-levels of plasma sodium after sildenafil treatment (148 mmol/l compared to 146 mmol/l at baseline). It seems safe to conclude that there was no beneficial effect of either sildenafil or riociguat on the urinary concentration ability.

A limitation of the present study is the small number of subjects included. However, with the extensive evaluation of each subject and no indication of an effect of either intervention, we believe that the data give proof of concept. The duration of the intervention (7 days) was shorter than that in the previously published pediatric case report (10 days),[@bib9] but given the half-life of sildenafil (3−5 hours) and riociguat (12 hours) and the clear blood pressure responses, it is unlikely that a beneficial effect would appear later than 7 days after initiating treatment. Both proteins PDE5 and sGC have been demonstrated in collecting ducts.[S9−S12](#appsec1){ref-type="sec"}

In summary, the current study found no beneficial effect of sildenafil and riociguat on urinary output or urinary concentration ability in 2 subjects with congenital NDI. It is concluded that in adult patients with congenital inherited NDI, caused by V2 receptor mutation, systemic pharmacological stimulation of the cGMP pathway, does not rescue the phenotype or improve urine concentration ability.

Disclosure {#sec3}
==========

All the authors declared no competing interests.

Supplementary Material {#appsec1}
======================

Supplementary File (pdf)

The authors thank the patients for their participation in the study. The authors are appreciative for the financial support from The Region of Southern Denmark.

Author Contributions {#sec4}
====================

GH, CB, HD, and BLJ developed the study design and hypothesis. GH and LM conducted the experiments. LM drafted the manuscript. GH prepared figures. GH, CB, HD, and BLJ critically revised the manuscript. All authors approved the final version of the manuscript.

[Supplementary File (PDF)](10.1016/j.ekir.2020.05.015){#intref0015}

**Supplementary Methods**.

**Supplementary References**.

[^1]: These authors contributed equally to this work.

[^2]: Crude urine samples obtained from the last hour during the 3 water deprivation tests.
